ZUG, Switzerland, April 04, 2024 Pharvaris , a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema attacks,.
Top-line data from Phase 2 CHAPTER-1 prophylactic study anticipated by YE2023Participated in an End-of-Phase 2 meeting with the FDA; initiation of global Phase 3 clinical study anticipated within.
SAN FRANCISCO, Aug. 03, 2022 (GLOBE NEWSWIRE) Today, Trio Health (Trio) and Augmedix (Nasdaq: AUGX), in partnership with the Consortium of Independent.